Hippo Holdings (HIPO) to Complete 1:25 Reverse Stock Split

Hippo Holdings Inc. (NYSE: HIPO), the home insurance group focused on proactive home protection, today announced that its Board of Directors has unanimously approved a 1-for-25 reverse stock split of the company’s common stock. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on Friday, September 30, 2022, under the existing trading symbol “HIPO” and new CUSIP number: 433539 202.

Upon the effectiveness of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive cash. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

About Hippo

Hippo is protecting the joy of homeownership, helping to safeguard customers’ most important financial asset by harnessing the power of real-time data, smart home technology, and a growing suite of home services to deliver proactive home protection.

Hippo Holdings Inc.’s (NYSE: HIPO) operating subsidiaries include Hippo Insurance Services, Hippo Home Care, First Connect Insurance Services, Spinnaker Insurance Company, Spinnaker Specialty Insurance Company, and Mainsail Insurance Company. Hippo Insurance Services is a licensed property casualty insurance agent with products underwritten by various affiliated and unaffiliated insurance companies. For more information, including licensing details, visit http://www.hippo.com.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Magna Holdings makes unsolicited bid for 31% of Yatra Online
• NorthStrive files two patents for muscle-loss drugs in spaceflight